Cytokine and hormone receptors

This entry refers to a broad classification of cell surface receptors, specifically cytokine and hormone receptors, that are targeted by a therapeutic modality known as fused ligands. Fused ligands are engineered chimeric proteins, such as Fc-fusions or albumin-fusions, designed to improve the pharmacokinetic properties, stability, and potency of natural ligands or receptor domains. These receptors typically belong to the type I and type II cytokine receptor families or the tumor necrosis factor receptor (TNFR) superfamily and are central to regulating immune responses, cell growth, and metabolic homeostasis. In clinical practice, drugs targeting these receptors include decoy receptors like etanercept, which traps circulating TNF, and long-acting agonists like dulaglutide, a GLP-1 receptor agonist. The platform-level classification designation indicates that this is a categorical grouping used for drug development and target identification rather than a single molecular entity. Dysregulation of these receptor pathways is a hallmark of many diseases, including rheumatoid arthritis, psoriasis, and various malignancies, making them high-priority targets for biotechnology platforms focused on protein engineering.

Other names

Cytokine receptorsHormone receptorsFused ligand targetsType I and II cytokine receptorsHematopoietin receptors

Fused ligands act as engineered agonists, antagonists, or decoy receptors (traps) that bind to their cognate cytokine or hormone receptors to modulate intracellular signaling pathways, often involving the JAK/STAT or TNFRSF cascades.